Eli Lilly (LLY) Notes Payables (2009 - 2014)

Eli Lilly (LLY) has 6 years of Notes Payables data on file, last reported at $1.0 billion in Q1 2014.

• For the quarter ending Q1 2014, Notes Payables fell 2.72% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2014 stood at $1.0 billion (down 2.72% YoY), and the FY2013 full-year result was $1.0 billion, up 8409.24% from the prior year.
• Notes Payables for Q1 2014 stood at $1.0 billion, down from $1.0 billion in the prior quarter.
• Across five years, Notes Payables topped out at $1.6 billion in Q3 2011 and bottomed at $9.1 million in Q2 2012.
• The 5-year median for Notes Payables is $578.0 million (2010), against an average of $667.6 million.
• The widest annual swing landed in 2012, when Notes Payables slumped 99.44%; it then soared 11143.96% in 2013.
• A 5-year view of Notes Payables shows it stood at $156.0 million in 2010, then jumped by 875.83% to $1.5 billion in 2011, then plunged by 99.22% to $11.9 million in 2012, then jumped by 8409.24% to $1.0 billion in 2013, then fell by 1.24% to $1.0 billion in 2014.
• The last three Notes Payables figures came in at $1.0 billion (Q1 2014), $1.0 billion (Q4 2013), and $1.0 billion (Q2 2013), per Business Quant data.

Peer Comparison